Form 4: Intuitive Surgical Executive Exercises Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical, executed stock options and sold shares of common stock under a pre-arranged trading plan.
Summary
- On September 10, 2024, Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical, exercised non-qualified stock options to acquire 119 shares of common stock at prices of $229.39 and $304.67 per share.
- Simultaneously, DeSantis sold 119 shares of common stock at a price of $477.50 per share.
- These transactions were executed under a pre-arranged trading plan that complies with SEC Rule 10b5-1 and expires on December 9, 2024.
- Following these transactions, DeSantis directly owns 5,506 shares of Intuitive Surgical common stock and holds options to purchase 3,472 additional shares at exercise prices of $229.39 and $304.67.
Sentiment
Score: 5
Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, which is neutral in sentiment.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating that the sales were planned in advance and not based on insider information.
Industry Context
Executive stock transactions are a normal part of corporate governance and compensation. The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without concerns about insider trading.
Comparison to Industry Standards
- Executive compensation packages at companies like Intuitive Surgical typically include stock options to align management's interests with those of shareholders.
- The vesting schedules described are fairly standard, with vesting occurring over several years of service.
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including competitors like Medtronic and Stryker, to manage their personal finances while avoiding potential insider trading issues.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on shareholders, as they are part of a pre-planned trading strategy.
- Employees may view the transactions as a sign of executive confidence in the company, but the impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 02/10/2023 | Date from which option vesting is measured for one tranche of options. |
| 08/10/2023 | Date from which option vesting is measured for another tranche of options. |
| 09/10/2024 | Date of the reported transactions (exercise of options and sale of shares). |
| 12/09/2024 | Expiration date of the 10b5-1 trading plan. |
| 02/27/2030 | Expiration date of one tranche of non-qualified stock options. |
| 08/09/2030 | Expiration date of another tranche of non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.